Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-372-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
The substance did not show signs of acute oral toxicity in rats in a GLP compliant study following OECD guideline 401.
During the acute dust expsosure study (GLP, OECD 403), rats exposed to 5 mg/L died of suffocation after the pigment dust blocked the airways. All rats survived the 4h dust exposure at the low dose of 1 mg/L. However, MPPD model simulations indicate that the results from the high dose group of the acute dust exposure study (GLP, OECD 403) in rats are not relevant for human health, since deviating internal exposure patterns of rat and humans were observed. The acute inhalation toxicity of the test substance was assessed based on a weight of evidence approach and expert judgement.
No data regarding the dermal acute toxicity are available.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Specific details on test material used for the study:
- - Synonyms: Copper tri/tetrachlorophthalocyanine pigment
- Substance type: blue powder
- Analytical purity: >85%
- Lot/batch No.: M200058
- Stability under test conditions: guaranteed for 4 hours
- Storage condition of test material: darkness at approx. 20 °C in a fume cupboard
- Other: different CAS No. are existing: 29719-96-8, 68987-63-3, 16040-69-0, 27614-71-7 - Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Winkelmann, Borchen, Germany
- Age at study initiation: 6-10 weeks
- Average weight at study initiation: males 189 g; females 178 g
- Fasting period before study: from ca. 16 h before to 3 - 4 h after treatment
- Housing: in fully air-conditioned rooms in macrolon cages (type 4) on soft wood granulate in groups of 5 animals
- Diet: ssniff (R) R/M-H (V 1534), ad libitum
- Water: tap water, ad libitum
- Acclimation period: at least 7 days
ENVIRONMENTAL CONDITIONS
- Temperature: 22 +- 3 °C
- Humidity: 50 +- 20 %
- Photoperiod: 12 hrs dark / 12 hrs light - Route of administration:
- oral: gavage
- Vehicle:
- other: sesame oil
- Details on oral exposure:
- The animals received the compound as a 20 % suspension in sesame oil, the administration volume being 10 ml/kg bw.
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 5 animals per sex per dose
- Control animals:
- no
- Details on study design:
- The prepared test substance was administered by gavage to fasted animals at the stated dosage. The observation period following treatment lasted for 14 days. Symptoms were recorded twice every day (in the morning and in the afternoon), on weekends and public holidays only once. During this time the animals were weighed weekly. At the end of the observation period, the animals were killed by CO2 asphyxilation, dissected and examined for macroscopically visible changes.
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Remarks on result:
- other: no mortality occurred
- Mortality:
- No deaths occured during the whole study.
- Clinical signs:
- other: Bluish discoloured feces were observed after the administration of the test material. From day 4 until the end of the study no findings were observed.
- Gross pathology:
- No macroscopically visible changes were seen.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the conditions of the limit test (accrding to OECD guideline 401) for acute toxicity after oral application, the LD50 for the test material is > 2000 mg/kg body weight for male and female rats.
Reference
Table 1: Individual body weights of rats
|
|
bodyweight (g) at day |
||
animal no. |
sex |
1 |
8 |
15 |
1 |
f |
176 |
196 |
220 |
2 |
f |
176 |
199 |
207 |
3 |
f |
178 |
207 |
216 |
4 |
f |
180 |
200 |
207 |
5 |
f |
178 |
216 |
203 |
1 |
m |
187 |
263 |
294 |
2 |
m |
189 |
261 |
298 |
3 |
m |
191 |
259 |
295 |
4 |
m |
182 |
228 |
268 |
5 |
m |
197 |
258 |
286 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- Valid without restriction
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- July - Sept 2021
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
- Specific details on test material used for the study:
- purity > 99%
Expiry date: 22 Feb 2031
Storage: Room temperature
physical appearance: solid/blue - Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services, Germany GmbH,
- Age at study initiation: on study day 0: male animals 54 – 64 days, female animals 54 – 80 days
- Weight at study initiation: animals of comparable weight (+/- 20% of the mean body weight)
- Fasting period before study: no
- Housing: single houing or up to 5 animals
- Diet: Kliba laboratory diet, ad libitum
- Water: tap water, ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature: 20–24 °C
- Humidity: 45-65 %
- Air changes: 15 changes per hour
- Photoperiod: 12 hours light / 12 hours dark - Route of administration:
- inhalation: dust
- Type of inhalation exposure:
- nose only
- Vehicle:
- air
- Mass median aerodynamic diameter (MMAD):
- > 1.9 - < 3 µm
- Geometric standard deviation (GSD):
- > 2.6 - < 3.2
- Remark on MMAD/GSD:
- Two samples were analyzed.
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: For each test group the dusts were produced inside the inhalation system with a brush dust generator and compressed air and passed into the inhalation system. The concentrations were adjusted by varying the apertural width rotation of the dosing wheel of the dust generator.
- Exposure chamber volume: 34 L
- Method of holding animals in test chamber: restraining tubes
- Source and rate of air: central air conditioning system,1.5 m³/h
- Method of conditioning air: Central air conditioning system provided cold air of about 15°C. This cold air passed through an activated charcoal filter, adjusted to room temperature of 20 to 24°C and passed through a second particle filter (H13 (HEPA) Camfil Farr, Germany). The so generated conditioned air was used to generate inhalation atmospheres.
- System of generating particulates/aerosols: The test item was stirred in its container before a sample for dust generation was taken. The test item was desagglomerated in a mixer (mixing for 10 seconds) before introduction into the dust generator via the dosing wheel (Gericke/BASF).
- Method of particle size determination: Stack Sampler Mark III (Andersen). Before sampling, impactor stages were assembled with preweighed glass fiber collecting discs, and equipped with a backup particle filter. The impactor was connected to a vacuum pump, and for each test group samples were taken from the breathing zone of the animals. Sampling occurred 30 minutes (or later) after the beginning of the exposure.
- Treatment of exhaust air: The exhaust air was filtered and conducted into the exhaust air of the building.
TEST ATMOSPHERE
- Brief description of analytical method used: gravimetric, filtration equipment with probe, internal diameter: 7 mm, Sampling velocity 1.25 m/s, 4 samples at about hourly intervals, Sampling Volume 15L (low dose) and 6L (high dose)
- Samples taken from breathing zone: yes
VEHICLE
none apart from air
TEST ATMOSPHERE:
- Particle size distribution: Based on cascade impactor measurements. The calculation of particle size distribution was carried out by means of mathematical methods for evaluating particle measurements. - Analytical verification of test atmosphere concentrations:
- yes
- Duration of exposure:
- 4 h
- Concentrations:
- 1 and 5 mg/L
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Individual body weight was determined once during the acclimatization period, at the start of the exposure period (Day 0) and at least on Days 1, 3 and 7, and weekly thereafter, or before the sacrifice of the animals at the end of the observation period.
- Clinical observations were recorded for each animal before exposure, separately several times during exposure (usually hourly) and after exposure. At least once daily on the preexposure day and during the post exposure observation period.
- Necropsy of survivors performed: yes
Pathology: At the end of the observation period the surviving animals were sacrificed with CO2-inhalation in a chamber with increasing concentration over time and were subjected to gross pathological examination as well as the animal which died before. To clarify the gross pathological findings, selected organs of individual animals were examined histopathologically. - Statistics:
- LC50 values were calculated for males, females and both sexes combined using a binomial test.
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 1.084 - < 5.212 mg/L air (analytical)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Remarks on result:
- other: High dose animals suffocated because the particles blocked the airways.
- Mortality:
- 5.212 mg/L: All of the male and female animals died. Lethality was observed either during exposure, after exposure on study day 0 or on study day 1 or study day 2.
1.084 mg/L: All animals survived. - Clinical signs:
- irregular respiration
- Body weight:
- 1.084 mg/L: The mean body weights of the animals decreased on the first post-exposure observation day but increased thereafter.
5.212 mg/L: The mean body weights of the surviving animals decreased during the first post-exposure observation days. No further body weight data were available for the animals because all animals died. - Gross pathology:
- 1.084 mg/L: No gross pathological findings were noted during the necropsy of the animals at the termination of the post-exposure observation period.
5.212 mg/L: During necropsy of the dead five male and five female animals, many black foci were seen in the lung lobes with sunken surface. Blue discoloration of content of the stomach was seen in four males and three females and blue depositions in the trachea were present in four males and two females. - Other findings:
- low dose (1 mg/L)
Clinical signs of toxicity in animals exposed to 1.084 mg/L comprised accelerated respiration, intermittent respiration, abdominal respiration, respiration sounds, feces substance like discolored, piloerection, substance-discolored fur and substance-contaminated fur. Findings were observed in the males from hour 1 of exposure through study day 11. No findings were detected in the male animals during the post-exposure observation period from study day 12 onwards. Findings were observed in the females from hour 1 of exposure until the end of the post-exposure observation period.
high dose (5 mg/L)
Clinical signs of toxicity in animals exposed to 5.212 mg/L comprised accelerated respiration, depressed respiration, abdominal respiration, no feces, activity: attention reduced, piloerection, substance-discolored fur and substance-contaminated fur. Findings were observed from hour 1 of exposure until the death of the animals. The mean body weights of the surviving animals decreased during the first post-exposure observation days. For further evaluation, histopathological examinations of the respiratory tract (nasal cavity, larynx, pharynx, trachea, and lung) from three animals were performed. The lung showed large amount of blue pigment within the bronchi, bronchioles and terminal bronchioles, leading to obstruction of the airways in two animals with one of them also showing emphysema. The trachea of all examined animals was dilated and contained blue pigment. The larynx at level I - II showed obstruction by blue pigment and large amounts of blue pigment at level III in 2 animals. The third animal presented with large amounts of blue pigment at larynx level I-II and small amounts at the third level. The nasal cavity at level I - IV contained small to moderate amounts of blue pigment.
The histopathological findings in the lung, the trachea, and the larynx of animal Nos. 793, 798 and 800 indicate an airway obstruction caused by the inhaled blue pigment as cause of death. - Interpretation of results:
- Category 4 based on GHS criteria
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- other: in silico
- Adequacy of study:
- weight of evidence
- Study period:
- 2022
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- The Multiple Path Particle Dosimetry (MPPD) model was used to predict aerosol deposition patterns representative of a guideline limit test acute inhalation toxicity study in the Sprague Dawley rat. Specifically, a 4-hr nose-only inhalation exposure to generic aerosol particles having a mass median aerosol diameter (MMAD) of 2.75 μm and a geometric standard deviation (GSD) of 1.0 (i.e., monodisperse distribution), a unit density of 1 g/cm3, and an airborne concentration of 5000 mg/m3 (5 mg/L) was simulated. Human simulations for a variety of hypothetical activity and breathing conditions for the same exposure were also conducted to highlight cross-species differences, although it is unlikely that such high aerosol exposures would be considered tolerable, even for non toxic materials.
- GLP compliance:
- no
- Test type:
- other: MPPD model
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- not applicable
- Route of administration:
- inhalation: dust
- Vehicle:
- air
- Mass median aerodynamic diameter (MMAD):
- 2.75 µm
- Geometric standard deviation (GSD):
- 1
- Duration of exposure:
- 4 h
- Concentrations:
- 5000 mg/m3 (5 mg/L)
- No. of animals per sex per dose:
- not applicable
- Control animals:
- other: not applicable
- Remarks on result:
- other: not applicable for test type
- Mortality:
- not applicable
- Clinical signs:
- other: not applicable
- Body weight:
- not applicable
- Gross pathology:
- not applicable
- Other findings:
- Rat Simulations
Aerosol Deposition in the Rat:
Slightly over 50% of respirable 2.75 μm particles deposited in the head (~32%; nose through larynx/throat) and conducting airways in the chest (~20-22%; tracheobronchial, TB) regions in both the Symmetric and Asymmetric rat models (Figure 1). With the enhanced variability in airway branching and surface areas associated with respiratory bronchioles that branch from upper conducting airways, not just the deep lung, slightly greater pulmonary deposition occurred in the Asymmetric (~4.7%) vs. the Symmetric (~3.7%) rat model.
Physiology profiles for each breathing mode are summarized in Table 1.
In the Symmetric Sprague Dawley rat model, tracheobronchial airways cover the first 13 generations with the generation 1 representing the trachea. Eight additional generations represented the pulmonary or gas-exchange region for a total of 21 generations in the Symmetric Sprague Dawley rat model (Table 2). MPPD provides multiple choices for dose metrics that can be used to compare across exposure scenarios, aerosol characteristics, and species. Of these options, deposition fraction, deposited mass (μg/breath), deposited mass rate (μg/min), total deposited over a single 4-hr exposure (μg) and total deposited mass/airway surface area (μg/cm2) for each airway generation for the Symmetric Sprague Dawley rat model are summarized in Table 2. Most of the deposited aerosol mass was predicted to occur in the tracheobronchial vs. pulmonary region. While significant amounts of deposited aerosol mass were predicted to deposit in the first three generations of pulmonary airways, when corrected for airway surface areas, the pulmonary region received very little deposited dose in 4 hr (μg/cm2) in the pulmonary airways of the symmetric lung model.
For the Asymmetric Sprague Dawley rat model, tracheobronchial airways cover the first 28 generations (generation 1 representing the trachea) with pulmonary airways branching off or tracheobronchial airways from generation 8—28 with an additional 8 generations terminating each complete tracheobronchial airway for a total of 36 generations (Table 3). This more accurate representation of the monopodial pulmonary airway branching system of the rat provides insights into the heterogeneities in local deposited aerosol doses in the lung than with the symmetric model. The same deposited dose metrics summarized in Table 2 for the symmetric model are shown in Table 3 for the entire lung (all airways in each generation) of the asymmetric mode. Several-fold differences between lobes were predicted. Such variability and differences in airway deposition between lobes in the asymmetric model can uncover local airway deposited dose differences that are masked using the symmetric model assumption. Airway generation-specific deposited mass as well as deposited mass per airway surface area are shown graphically in Figure 4. A larger fraction of pulmonary airways was exposed to inhaled aerosols without penetrating as deep into the tracheobronchial region in the asymmetric (monopodial) lung model than would be predicted with the simpler, symmetric (bipodial) lung airway model. However, when normalized to airway surface area, the deposited doses (μg/cm2) in the pulmonary regions were similar between the two models.
Theoretical Distribution of Aerosol Deposition Within the Head Region of the Rat:
The MPPD model uses a simple empirical model to determine aerosol deposition in the head region (nose through larynx) of rats without differentiating local regions within the head that are common target sites for deposition and potential toxicity in inhalation studies due to their unique airway anatomy and breathing patterns. However, a recently published computational fluid particle dynamics (CFPD) model provided site-specific deposition patterns in the upper conducting airways of the Sprague Dawley rat with comparable aerosol exposures that can inform the results from the MPPD simulations as both the CFPD and MPPD models utilized the same source of CT-derived airway geometry data (Figure 5; Corley et al., 2021).
In the CFPD rat model, regional deposition fractions in the nasal vestibule (dry squamous epithelium); wet squamous, respiratory, transitional, and olfactory epithelium; and the nasopharynx and larynx regions were determined for a single breath of exposure to 2.72 μm MMAD aerosols at 4.03 mg/L air concentration (Figure 5). The main differences between the simulations were with the simplified one-dimensional airway geometry used in the empirical MPPD head model vs. the actual three-dimensional airway geometry used in the CFPD model and the respective breathing profiles used in each simulation (CFPD: 217 ml minute volume at 100 bpm; MPPD: 353 ml minute volume, 166 bpm). In addition, the use of an inhalability correction in MPPD which reduced the inhalable fraction to 0.79, but not with the CFPD simulation (no inhalability adjustment) was largely responsible for differences in total inhaled fractions deposited in the head regions between the two models (CFPD: 0.59 vs. MPPD: 0.32).
Regardless, estimated fractional deposition of inhalable aerosols within each head region of the CFPD model could still be used to normalize the total fraction deposited from the MMPD head simulations to corresponding theoretical regions within the Symmetric and Asymmetric Sprague Dawley rat models (Table 4). Thus, most inhalable aerosols from the MPPD simulations are predicted to deposit in the anterior most portions of the nose (nasal vestibule and wet squamous epithelium) followed by the most anterior portions of respiratory and transitional epithelium of the nasoturbinates and maxilloturbinates, and larynx. Of these tissues, the anterior portions of respiratory and transitional epithelium of the nasoturbinates and maxilloturbinates and the larynx are common target sites for inhaled materials that produce local inflammation, irritation, or cytotoxicity in the head region. Since the Symmetric and Asymmetric Sprague Dawley rat models utilized the same empirical head model, results for the two models were essentially the same.
Tracheobronchial and Pulmonary Airway Clearance in the Rat:
While cumulative deposited dose (total mass or mass per airway or regional surface areas) may be appropriate dose-metrics for short-term acute exposures, they are not appropriate for repeated or long-term exposures as particle clearance mechanisms can play a significant role in respiratory tissue exposures (Brown et al., 2005; Corley et al, 2021). The MPPD model includes equations for mucociliary clearance in the tracheobronchial airways and macrophage clearance for the pulmonary regions of the rat and human. No clearance model is currently available in MPPD for the head region of any species.
The effect of mucociliary clearance in the tracheobronchial region is the most dramatic as the only 22-27% of the cumulative deposited mass (87—93 mg) in the tracheobronchial region of the whole lung of the Symmetric and Asymmetric Sprague Dawley rat simulations were retained at the end of exposure (Table 5). Following the 4-hr exposure, the retained mass was rapidly cleared within the first 12 hr from the start of the exposures with <0.1% remaining after 7 days.
For the pulmonary region, the slow clearance rate by macrophages results in minimal clearance of the cumulative deposited dose both during the exposure and for up to 7 days postexposure leading a higher retained mass (9.94 —13.6 mg) in each model (Table 5). Even with the slow clearance, the retained dose per pulmonary airway surface area remains low, but persistent. Given the pulmonary lung burden of 16-20 mg and over 100 mg when the tracheobronchial region is included at the end of the 4-hr exposure, it is possible that particle overload could occur that reduces clearance rates at this aerosol concentration, potentially confounding results and ability to extrapolate to the human (Bevan et al., 2018).
Potential for Obstructive Disruption of Airway Function in the Rat:
While MPPD is not designed to specifically address the question of whether deposited aerosols can be of sufficient magnitude to alter local airflows and thus, airway function, the significant amounts of aerosol that deposit and are retained in individual bronchiolar and pulmonary regions of the Symmetric and Asymmetric Sprague Dawley rat simulations suggest that the potential for disruption in airflows and lung function are possible. To assess this possibility, the total mass of aerosol particles that were retained in each tracheobronchial and pulmonary airway at the end of the 4-hr exposure were assumed to coalesce into a single spherical mass whose dimensions (diameter) were then compared with each airway diameter. To be clear, MPPD has no equations describing the influence of particles on airflows included in the current mode versions. Thus, while significant deposition and accumulation certainly occurs in discrete regions within each airway over a 4-hr exposure especially in pulmonary regions with slower clearance rates, this comparative calculation from MPPD results represents a worst-case scenario.
Given this scenario, the ratios of the diameters of the total retained mass in each airway to the diameters of corresponding airways in the Symmetric and Asymmetric Sprague Dawley rat simulations were determined at the end of the 4-hr exposure. As the ratios for each airway generation (Symmetric model) or airway within each generation (Asymmetric model) approaches unity, the potential for airflow obstruction increases. The results of this analysis for each generation of the Symmetric Sprague Dawley rat model are all below 1.0 but several generations have ratios >0.5 indicating some airways may be especially vulnerable to altered airflows.
The Asymmetric Sprague Dawley rat model provides a significantly more detailed assessment as nearly 40,000 airway segments are specifically defined according to realistic measurements from high resolution CT scans of silicone lung casts where pulmonary airways begin branching off of bronchiolar airways as high as generation 8, not just the terminal bronchiolar region as assumed in the Symmetric Sprague Dawley rat model in MPPD (Table 3), leading to a greater number of small diameter airways being exposed to higher airway concentrations of aerosol than occurs in the deep lung. In this model, ratios of retained aerosol mass diameters to their corresponding airway diameters of the tracheobronchial and pulmonary regions show a significant number of airways with ratios >0.5 and in some cases, ratios significantly >1.0. For the tracheobronchial region, most airways (4925 or 59.1%) have ratios between 0.25 and 0.5. For ratios >0.5, 23% or 1,915 airways are between 0.5 and 1.0 with 6.2% of airways (517 airways) with ratios >1.0. For the pulmonary region, the number and percentages of airways are increased, with over 42% having ratios >0.5 which is consistent with their smaller airway diameters and the high numbers of airways that branch off from upper bronchiolar airways.
While this computational analysis of model simulations is worst-case, it does reveal that the total mass deposited and retained by many airways at the end of 4 hr of exposure can be significant and may potentially lead to obstructive losses in function that is not reflective of chemical-specific toxicity. The higher up the airway generations this occurs, the greater the effect on associated downstream pulmonary gas-exchange regions. There is experimental evidence that phenomenon occurs based upon histopathologic observations from rats exposed in acute 4-hr studies to 5 mg/L aerosol concentrations of materials with high hydrophobicity and greater likelihood to clump up rather than disperse on airway surfaces when deposited (Hofmann et al., 2018). The result from this hypothetical computational analysis from a biological and aerosol physics based mechanistic model like MPPD supports these experimental observations.
Species Comparisons:
For 2.75 μm-sized aerosols, only 79.2% of atmospheric aerosols are inhalable by the rat while 100% is respirable for the human. For nasal breathing under resting ventilation conditions, approximately 32% of respirable 2.75 μm aerosols deposit in the head of the rat vs. 50% in the human. For the tracheobronchial region, nearly twice the fractional deposition occurred in the rat (20-22%) vs. only 8% in the human. Overall, there is a generally greater fractional pulmonary deposition of 2.75 μm aerosols in the human (20-33%) than in the rat (3.7- 4.7%). There is also a shift toward significantly less deposition in the head and greater pulmonary deposition and deeper penetration into pulmonary airways following oral breathing in humans.
When cumulative deposited mass is normalized to respective airway surface areas, the rat receives ~5-10-fold higher dose/cm2 airway surface in the tracheobronchial regions than the human under resting nasal breathing ventilation conditions, This margin is reduced between species in the first 2-4 generations of the conducting airways for human nasal breathing under light exercise conditions. When the cumulative deposited mass per cm2 airway surface in the rat is compared with human oral breathing the differences between species is similar under resting conditions but light or even heavy exercise results in deposited mass per cm2 airway surface that are near or even exceeding the equivalent surface area normalized dose in the first 2-5 generations of bronchial airways.
Both species have very low cumulative deposited mass/cm2 airway surface in the pulmonary regions but what mass is deposited is very slowly cleared with over 87% retained over 7 days in the rat (asymmetric model) and over 97% retained in the human (all breathing and activity conditions). Mucociliary clearance is faster in the tracheobronchial airways of the rat than in the human with the time to clear at least 95% of retained mass in tracheobronchial airways is ~12 hr for rats vs. ~48-72 hr for humans depending upon breathing mode and activity pattern.
These comparisons between species are limited to the same exposure conditions for a generic aerosol to highlight the impact of species-specific anatomy and physiology on aerosol deposition. If toxicity in the respiratory airways of the rat was an outcome of this exposure scenario, MPPD can also be used to calculate the human equivalent exposure concentrations (HEC) for a variety of scenarios that result in the same target region delivered or, preferably, retained doses from the simulations of the rat exposure under bioassay conditions. - Interpretation of results:
- study cannot be used for classification
- Conclusions:
- This analysis showed that a significant percentage of pulmonary airways and to a lesser extent, bronchiolar airways, may be at risk of occlusion and impairment of lung function and gas exchange in the rat. Such a potential for physical impact on lung function for certain materials that are presumed to be of low toxicity raises questions for assessing acute toxicity risks for humans based upon guideline acute toxicity studies in the rat at limit test concentrations.
- Executive summary:
Rats are obligate nose breathers and with over 30% of inhalable aerosol depositing in the head region, anterior nasal tissues and laryngeal regions are likely to receive a significant amount of deposition based upon a computational fluid-particle dynamics (CFPD)-informed analysis of MPPD simulations. Given the smaller airways and higher breathing frequencies and minute volumes per unit body weight in rats vs. humans, greater amounts of aerosol mass are deposited in the tracheobronchial region in rats, while in humans, a greater mass is deposited in the pulmonary region. However, when normalized to airway surface areas, both species receive a relatively low overall pulmonary regional dose. Mucociliary clearance rates are also slower in humans than in the rat and the time to clear tracheobronchial airways varies between ~48 and 72 hr depending upon breathing mode and activity level vs. ~12 hr in the rat. Both species have slow macrophage clearance rates in the pulmonary region with neither species clearing much material (<87-97% of deposited mass) by 7 days. However, given the smaller airways in the rat and the potential for significant amounts of deposited and retained mass of aerosols in individual airways, the potential for airway obstruction and resulting decreases in airflows and pulmonary function was assessed in individual airways using a geometric analysis of MPPD simulations. This analysis showed that a significant percentage of pulmonary airways and to a lesser extent, bronchiolar airways, may be at risk of occlusion and impairment of lung function and gas exchange in the rat.
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- other: in silico
- Adequacy of study:
- weight of evidence
- Study period:
- 2022
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- The Multiple Path Particle Dosimetry (MPPD) model was used to predict aerosol deposition patterns representative of a guideline limit test acute inhalation toxicity study in the Sprague Dawley rat. Specifically, a 4-hr nose-only inhalation exposure to generic aerosol particles having a mass median aerosol diameter (MMAD) of 2.75 μm and a geometric standard deviation (GSD) of 1.0 (i.e., monodisperse distribution), a unit density of 1 g/cm3, and an airborne concentration of 5000 mg/m3 (5 mg/L) was simulated. Human simulations for a variety of hypothetical activity and breathing conditions for the same exposure were also conducted to highlight cross-species differences, although it is unlikely that such high aerosol exposures would be considered tolerable, even for non toxic materials.
- GLP compliance:
- no
- Test type:
- other: MPPD model
- Limit test:
- yes
- Species:
- other: human
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- not applicable
- Route of administration:
- inhalation: dust
- Vehicle:
- air
- Mass median aerodynamic diameter (MMAD):
- 2.75 µm
- Geometric standard deviation (GSD):
- 1
- Duration of exposure:
- 4 h
- Concentrations:
- 5000 mg/m3 (5 mg/L)
- No. of animals per sex per dose:
- not applicable
- Control animals:
- other: not applicable
- Remarks on result:
- other: not applicable for test type
- Mortality:
- not applicable
- Clinical signs:
- other: not applicable
- Body weight:
- not applicable
- Gross pathology:
- not applicable
- Other findings:
- Human Simulations
Aerosol Dosimetry in the Human:
Following nasal breathing under resting conditions, 50.5% of the inhaled fraction of aerosols deposited in the head, while 8.4% deposited in the tracheobronchial and 19.6% in the pulmonary regions (79% total; Figure 9). Under light exercise conditions, the inhaled fraction of aerosols depositing in the head following nasal breathing increased from 50.5 to 80% while deposition correspondingly decreased in tracheobronchial (8.4 to 3.0%) and pulmonary regions (19.6 to 10.5%).
This is in contrast with oral breathing where under resting conditions only 3.1% deposited in the head, 13.2% deposited in the tracheobronchial and 30.8% deposited in the pulmonary regions (47.1% total; Figure 9). Under light exercise conditions, deposition in the head also increased for oral breathing (3.1 to 6.4%) with a corresponding decrease in deposition in tracheobronchial (13.2 to 8.6%) but little change in pulmonary regions (30.8 to 30.4%).
For oral breathing with normal nasal augmentation that commonly occurs under heavy exercise conditions, deposition of inhaled aerosols was 48% in the head, 6.6% in the tracheobronchial and 17.6% in pulmonary regions. Physiology profiles for each breathing mode are summarized in Table 1.
Similar in structural organization to the Symmetric Sprague Dawley rat model, the Symmetric Yeh and Schum human model consists of 17 generations of tracheobronchial airways (trachea is generation 1) with 7 generations of pulmonary airways appended to each terminal bronchiole airway for a total of 24 generations. Several potential dose-metrics for acute exposures, including deposition fractions, deposited mass, deposition rate and total deposited mass, number of particles and mass/cm2 airway surface by generation for each breathing modality in the Symmetric Yeh and Schum human model are summarized in Tables 6 to 10.
Deposition fractions and cumulative deposited mass per generation over 4-hr exposures were significantly greater in pulmonary than tracheobronchial regions for each breathing modality with a general shift towards deeper pulmonary airway generations during exercise and with oral vs. nasal breathing. However, with the large airway surfaces in the pulmonary region, the cumulative deposited mass in 4 hr per airway surface area remained significantly lower in pulmonary regions with the greatest cumulative surface area normalized dose occurring in the first few generations of tracheobronchial airways (Figure 12).
Theoretical Distribution of Aerosol Deposition Within the Head Region of the Human:
As with the rat, the theoretical distributions of airway deposition across cell type or anatomic region (Figure 5) in the empirical head region of the Symmetric Yeh and Schum MPPD simulations for resting oral and nasal breathing were calculated using published CFPD simulations and are summarized in Table 4b (Corley et al., 2021). Based upon these calculations, the respiratory epithelium and the larynx are predicted to receive the greatest deposited fractions and cumulative deposited masses of aerosols following nasal breathing vs. the mouth and larynx following oral breathing. While each of these regions have high rates of aerosol clearance (ICRP, 2015), depending upon the aerosol toxicity mode of action, the nasal respiratory epithelium (nasal breathing) and larynx (both nasal and oral breathing) could represent tissues of potential concern just based upon local deposited dose in the head region of MPPD following exposures to such high concentrations of aerosols of this size (5 mg/L, 2.75 μm) unless cell-specific sensitivity factors across this region are known and suggest otherwise.
Tracheobronchial and Pulmonary Airway Clearance in the Human:
Mucociliary clearance rates are typically slower in humans than in rats. The deposited masses retained in tracheobronchial airways following each breathing mode ranged from 53 to 81% of the cumulative amounts deposited during the 4 hr exposure with over 95% cleared by 72 hr and 97% by 7 days (Table 5). For the pulmonary airways, very little deposited mass was cleared during the 4- hr exposure with less than 5% cleared over 7 days for any breathing mode (Table 5).
Species Comparisons:
For 2.75 μm-sized aerosols, only 79.2% of atmospheric aerosols are inhalable by the rat while 100% is respirable for the human. For nasal breathing under resting ventilation conditions, approximately 32% of respirable 2.75 μm aerosols deposit in the head of the rat vs. 50% in the human. For the tracheobronchial region, nearly twice the fractional deposition occurred in the rat (20-22%) vs. only 8% in the human. Overall, there is a generally greater fractional pulmonary deposition of 2.75 μm aerosols in the human (20-33%) than in the rat (3.7- 4.7%). There is also a shift toward significantly less deposition in the head and greater pulmonary deposition and deeper penetration into pulmonary airways following oral breathing in humans.
When cumulative deposited mass is normalized to respective airway surface areas, the rat receives ~5-10-fold higher dose/cm2 airway surface in the tracheobronchial regions than the human under resting nasal breathing ventilation conditions, This margin is reduced between species in the first 2-4 generations of the conducting airways for human nasal breathing under light exercise conditions. When the cumulative deposited mass per cm2 airway surface in the rat is compared with human oral breathing the differences between species is similar under resting conditions but light or even heavy exercise results in deposited mass per cm2 airway surface that are near or even exceeding the equivalent surface area normalized dose in the first 2-5 generations of bronchial airways.
Both species have very low cumulative deposited mass/cm2 airway surface in the pulmonary regions but what mass is deposited is very slowly cleared with over 87% retained over 7 days in the rat (asymmetric model) and over 97% retained in the human (all breathing and activity conditions). Mucociliary clearance is faster in the tracheobronchial airways of the rat than in the human with the time to clear at least 95% of retained mass in tracheobronchial airways is ~12 hr for rats vs. ~48-72 hr for humans depending upon breathing mode and activity pattern.
These comparisons between species are limited to the same exposure conditions for a generic aerosol to highlight the impact of species-specific anatomy and physiology on aerosol deposition. If toxicity in the respiratory airways of the rat was an outcome of this exposure scenario, MPPD can also be used to calculate the human equivalent exposure concentrations (HEC) for a variety of scenarios that result in the same target region delivered or, preferably, retained doses from the simulations of the rat exposure under bioassay conditions. - Interpretation of results:
- study cannot be used for classification
- Conclusions:
- This analysis showed that a significant percentage of pulmonary airways and to a lesser extent, bronchiolar airways, may be at risk of occlusion and impairment of lung function and gas exchange in the rat. Such a potential for physical impact on lung function for certain materials that are presumed to be of low toxicity raises questions for assessing acute toxicity risks for humans based upon guideline acute toxicity studies in the rat at limit test concentrations.
- Executive summary:
In general, greater deposition of aerosols occurs in the head region of humans following nasal than with oral breathing. However, oral breathing and increased activity (increased bpm and minute volume) can lead to deeper penetration of aerosols within the pulmonary region. Given the smaller airways and higher breathing frequencies and minute volumes per unit body weight in rats vs. humans, greater amounts of aerosol mass are deposited in the tracheobronchial region in rats, while in humans, a greater mass is deposited in the pulmonary region. However, when normalized to airway surface areas, both species receive a relatively low overall pulmonary regional dose. Mucociliary clearance rates are also slower in humans than in the rat and the time to clear tracheobronchial airways varies between ~48 and 72 hr depending upon breathing mode and activity level vs. ~12 hr in the rat. Both species have slow macrophage clearance rates in the pulmonary region with neither species clearing much material (<87-97% of deposited mass) by 7 days.
Referenceopen allclose all
Table 1: Clinical signs and duration in the low concentration group
Test group 1 (1.084 mg/L) |
Male animals |
Female animals |
Feces, discolored feces,substance like |
d1 |
d1 |
Fur, discolored, substance like |
d2 – d11 |
d2 – d14 |
Fur, piloerection |
d0 – d1 |
d0 – d1 |
Fur, substance-contaminated |
d0 – d1 |
d0 – d1 |
Respiration, abdominal |
- |
d0 – d1 |
Respiration, accelerated |
h1 – d4 |
h1 – d4 |
Respiration, intermittent |
d5 – d6 |
d5 – d6 |
Respiration, sounds |
d2 – d4 |
d2 – d4 |
No findings were detected in the male animals during the post-exposure observation period from study day 12 onwards.
Table 2: Clinical signs and duration, high concentration group
Test group 2 (5.212 mg/L) |
Male animals |
Female animals |
Lethality (number of animals) |
5 / 5 |
5 / 5 |
Activity/behavior, attention reduced |
d0 |
d0 – d1 |
Feces, no feces |
- |
d1 |
Fur, discolored, substance like |
d0 |
d0 – d1 |
Fur, piloerection |
d0 |
d0 – d1 |
Fur, substance-contaminated |
d0 |
d0 |
Respiration, abdominal |
d0 |
d0 – d1 |
Respiration, accelerated |
h1 – h2 |
h1 – h2 |
Respiration, depressed |
h3 – h4 |
h3 – h4 |
Table 3: Necropsy findings in animals that died during the study period
Findings |
high concentration |
Number of animals |
5 males + 5 females |
Lung: many black foci in all lobes (Æ4 mm), surface sunken |
1 male + 3 females |
Lung: many black foci in all lobes (Æ8 mm), surface sunken |
4 males + 2 females |
Stomach: blue discoloration of the content |
4 males + 2 females |
Trachea: blue deposition |
4 males + 2 females |
Table 4: Necropsy findings of animals at termination of the post exposure period
Findings |
low concentration |
Number of animals |
5 males + 5 females |
Organs without particular findings |
5 males + 5 females |
Table 5: Histopathology findings
Animal No.: |
|||
|
793 |
798 |
800 |
Lung |
|
|
|
Bronchi, bronchioles and terminal bronchioles contain large amount of blue pigment |
x |
- |
- |
Bronchi, bronchioles and terminal bronchioles contain large amount of blue pigment, which obstructs the lumen |
- |
x |
- |
Bronchi, bronchioles and terminal bronchioles contain large amount of blue pigment, which obstructs the lumen, emphysema |
- |
- |
x |
|
|
|
|
Trachea |
|
|
|
Dilation, contains blue pigment |
x |
x |
x |
|
|
|
|
Larynx |
|
|
|
Level I Obstructed by blue pigment |
x |
- |
x |
Level I Contains large amounts of blue pigment |
- |
x |
- |
Level II Obstructed by blue pigment |
x |
- |
x |
Level II Contains large amounts of blue pigment, edema |
- |
x |
- |
Level III Contains large amounts of blue pigment |
x |
- |
x |
Level III Contains small amounts of blue pigment |
- |
x |
- |
|
|
|
|
Nasalcavity |
|
|
|
Level IContains small amounts of blue pigment |
x |
x |
x |
Level II Contains small amounts of blue pigment |
x |
- |
x |
Level II Contains moderate amounts of blue pigment |
|
x |
|
Level III Contains small amounts of blue pigment |
x |
x |
x |
Level IV Contains small amounts of blue pigment |
x |
x |
x |
Table 2. Aerosol deposition by generation (all airways in each generation) in the Symmetric Sprague Dawley rat model (EPA v1.01) following a 4-hr exposure to 2.75 µm MMAD particles at 5 mg/L air concentration.
Generation |
Structure |
No. Airways |
Surface Area (cm2) |
Deposited Fraction |
Deposited Mass (µg/Breath) |
Deposited Mass Rate (µg/min) |
Total Deposited Mass, 4-hr (µg) | Total Deposited Mass, 4- hr/Surface Area (µg/cm2) |
1 | Trachea | 1 | 0.50 | 2.60E-04 | 0.0028 | 0.46 | 109.9 | 220.9 |
2 | Main Bronchi | 2 | 0.55 | 1.82E-02 | 0.1933 | 32.08 | 7,699.2 | 13,957.9 |
3 | Bronchi(ole) | 4 | 0.76 | 1.59E-02 | 0.1686 | 27.99 | 6,717.6 | 8,868.1 |
4 | Bronchi(ole) | 8 | 0.81 | 1.57E-02 | 0.1664 | 27.62 | 6,628.8 | 8,167.6 |
5 | Bronchi(ole) | 16 | 0.82 | 2.39E-02 | 0.2544 | 42.24 | 10,137.6 | 12,299.9 |
6 | Bronchi(ole) | 32 | 0.87 | 2.62E-02 | 0.2790 | 46.31 | 11,114.4 | 12,756.1 |
7 | Bronchi(ole) | 64 | 0.98 | 2.60E-02 | 0.2760 | 45.81 | 10,994.4 | 11,227.9 |
8 | Bronchi(ole) | 128 | 1.18 | 2.72E-02 | 0.2894 | 48.04 | 11,529.6 | 9,795.8 |
9 | Bronchi(ole) | 256 | 1.70 | 2.38E-02 | 0.2533 | 42.05 | 10,092.0 | 5,950.5 |
10 | Bronchi(ole) | 512 | 2.65 | 1.74E-02 | 0.1849 | 30.70 | 7,368.0 | 2,777.2 |
11 | Bronchi(ole) | 1024 | 4.28 | 1.11E-02 | 0.1177 | 19.54 | 4,689.6 | 1,095.4 |
12 | Bronchi(ole) | 2048 | 7.74 | 7.60E-03 | 0.0808 | 13.40 | 3,216.0 | 415.7 |
13 | Bronchi(ole) | 4096 | 12.59 | 6.76E-03 | 0.0718 | 11.93 | 2,863.2 | 227.4 |
14 | Prox.AlvRegion | 8,192 | 35.72 | 9.81E-03 | 0.1043 | 17.31 | 4,154.4 | 116.3 |
15 | Prox.AlvRegion | 16,384 | 60.06 | 1.88E-02 | 0.2002 | 33.24 | 7,977.6 | 132.8 |
16 | DistalAlvRegion | 32,768 | 90.96 | 8.26E-03 | 0.0878 | 14.58 | 3,499.2 | 38.5 |
17 | DistalAlvRegion | 65,536 | 169.70 | 0 | 0 | 0 | 0 | 0 |
18 | DistalAlvRegion | 131,072 | 330.80 | 0 | 0 | 0 | 0 | 0 |
19 | DistalAlvRegion | 262,144 | 670.10 | 0 | 0 | 0 | 0 | 0 |
20 | DistalAlvRegion | 524,288 | 1,132.00 | 0 | 0 | 0 | 0 | 0 |
21 | DistalAlvRegion | 1,048,576 | 2,478.00 | 0 | 0 | 0 | 0 | 0 |
Table 3. Aerosol deposition by generation in entire lung (all airways in each generation) in the Asymmetric Sprague Dawley rat model (EPA v1.01) following a 4-hr exposure to 2.75 µm MMAD particles at 5 mg/L air concentration.
Generation |
Structure | TB Surface Area (cm2) |
Pulmonary Surface Area (cm2) | Combined Surface Area (cm2) |
Deposition Fraction |
Deposited Mass (µg/Breath) | Deposited Mass Rate (µg/min) | Total Deposited Mass 4-hr (µg) |
Total Dep Mass 4-hr (µg/cm2) |
1 | TB | 0.37 | 0 | 0.37 | 2.23E-04 | 2.37E-03 | 0.39 | 94.4 | 252.73 |
2 | TB | 0.39 | 0 | 0.39 | 2.70E-02 | 0.2868 | 47.61 | 11426.1 | 29163.12 |
3 | TB | 0.58 | 0 | 0.58 | 2.14E-02 | 0.227 | 37.68 | 9043.7 | 15512.32 |
4 | TB | 0.57 | 0 | 0.57 | 1.22E-02 | 0.1296 | 21.51 | 5163.3 | 9009.36 |
5 | TB | 0.76 | 0 | 0.76 | 1.07E-02 | 0.1141 | 18.94 | 4545.7 | 5976.52 |
6 | TB | 0.76 | 0 | 0.76 | 9.57E-03 | 0.1017 | 16.88 | 4051.7 | 5365.11 |
7 | TB | 0.97 | 0 | 0.97 | 1.17E-02 | 0.1238 | 20.55 | 4932.2 | 5069.06 |
8 | TB+Pulm | 1.02 | 0.00 | 1.02 | 1.28E-02 | 0.1358 | 22.54 | 5410.3 | 5293.81 |
9 | TB+Pulm | 1.39 | 0.02 | 1.41 | 1.27E-02 | 0.1353 | 22.46 | 5390.4 | 3828.38 |
10 | TB+Pulm | 1.87 | 0.15 | 2.01 | 1.43E-02 | 0.1519 | 25.22 | 6051.7 | 3006.31 |
11 | TB+Pulm | 1.99 | 0.55 | 2.54 | 1.36E-02 | 0.1449 | 24.05 | 5772.8 | 2277.24 |
12 | TB+Pulm | 2.36 | 1.69 | 4.06 | 1.25E-02 | 0.1328 | 22.04 | 5290.8 | 1304.75 |
13 | TB+Pulm | 2.38 | 4.00 | 6.38 | 1.25E-02 | 0.133 | 22.08 | 5298.7 | 830.26 |
14 | TB+Pulm | 2.25 | 8.73 | 10.98 | 1.10E-02 | 0.1173 | 19.47 | 4673.2 | 425.61 |
15 | TB+Pulm | 2.14 | 18.09 | 20.23 | 1.07E-02 | 0.1135 | 18.84 | 4521.8 | 223.52 |
16 | TB+Pulm | 1.94 | 35.77 | 37.71 | 1.04E-02 | 0.1108 | 18.39 | 4414.3 | 117.06 |
17 | TB+Pulm | 1.60 | 68.51 | 70.11 | 9.25E-03 | 0.0984 | 16.33 | 3920.3 | 55.92 |
18 | TB+Pulm | 1.40 | 113.30 | 114.70 | 8.22E-03 | 0.0873 | 14.49 | 3478.0 | 30.32 |
19 | TB+Pulm | 1.13 | 168.80 | 169.90 | 7.34E-03 | 0.078 | 12.95 | 3107.5 | 18.29 |
20 | TB+Pulm | 0.81 | 201.20 | 202.00 | 6.08E-03 | 0.0646 | 10.72 | 2573.7 | 12.74 |
21 | TB+Pulm | 0.59 | 234.10 | 234.60 | 4.68E-03 | 0.0497 | 8.25 | 1980.0 | 8.44 |
22 | TB+Pulm | 0.32 | 240.10 | 240.40 | 3.81E-03 | 0.0405 | 6.72 | 1613.5 | 6.71 |
23 | TB+Pulm | 0.18 | 217.60 | 217.80 | 3.03E-03 | 0.0322 | 5.35 | 1282.8 | 5.89 |
24 | TB+Pulm | 0.08 | 204.10 | 204.20 | 2.39E-03 | 0.0254 | 4.22 | 1011.9 | 4.96 |
25 | TB+Pulm | 0.06 | 177.60 | 177.70 | 1.66E-03 | 0.0177 | 2.94 | 705.2 | 3.97 |
26 | TB+Pulm | 0.05 | 160.70 | 160.70 | 1.11E-03 | 0.0118 | 1.96 | 470.1 | 2.93 |
27 | TB+Pulm | 0.02 | 129.20 | 129.20 | 6.38E-04 | 6.78E-03 | 1.13 | 270.1 | 2.09 |
28 | TB+Pulm | 0.01 | 99.50 | 99.51 | 3.13E-04 | 3.33E-03 | 0.55 | 132.7 | 1.33 |
29 | Pulmonary | 0 | 65.94 | 65.94 | 1.47E-04 | 1.56E-03 | 0.26 | 62.2 | 0.94 |
30 | Pulmonary | 0 | 36.32 | 36.32 | 7.46E-05 | 7.93E-04 | 0.13 | 31.6 | 0.87 |
31 | Pulmonary | 0 | 20.11 | 20.11 | 3.77E-05 | 4.00E-04 | 0.07 | 15.9 | 0.79 |
32 | Pulmonary | 0 | 10.06 | 10.06 | 1.42E-05 | 1.51E-04 | 0.03 | 6.0 | 0.60 |
33 | Pulmonary | 0 | 5.59 | 5.59 | 3.65E-08 | 3.88E-07 | 0.00 | 0.0 | 0.00 |
34 | Pulmonary | 0 | 3.91 | 3.91 | 0 | 0 | 0 | 0.0 | 0 |
35 | Pulmonary | 0 | 1.12 | 1.12 | 0 | 0 | 0 | 0.0 | 0 |
36 | Pulmonary | 0 | 0.56 | 0.56 | 0 | 0 | 0 | 0.0 | 0 |
Table 4. Theoretical distributions of the fractions of deposited mass estimated for the head region of the rat MPPD simulations based upon published computational fluid particle dynamics (CFPD) simulations with comparable aerosols (Corley et al., 2001).
From Table 2, Corley et al. (2021) | Normalized Deposition in MPPD Head Region (EPA v1.01) Symmetric SD Rat | Normalized Deposition in MPPD Head Region (EPA v1.01) Asymmetric SD Rat | ||||||||
Airway Region |
Surf. Area (cm2) |
Dep. Fract. |
Est. Dep. Fract. |
Est. Dep Mass Rate (µg/Breath) | Est. Dep Mass Rate (µg/min) |
Est. Total Dep Mass 4-hr (µg) |
Est. Dep. Fract. |
Est. Dep Mass Rate (µg/Breath) | Est. Dep Mass Rate (µg/min) |
Est. Total Dep Mass 4-hr (µg) |
Vestibule, Dry Squamous |
0.45 |
0.5310 |
0.2900 |
3.08 |
511.6 |
122,786.0 |
0.2915 |
3.10 |
514.3 |
123,439.0 |
Wet Squamous |
0.63 |
0.0483 |
0.0264 |
0.28 |
46.5 |
11,170.6 |
0.0265 |
0.28 |
46.8 |
11,230.0 |
Respiratory | 5.69 | 0.0010 | 0.0005 | 0.01 | 0.9 | 227.0 | 0.0005 | 0.01 | 1.0 | 228.2 |
Transitional | 2.16 | 0.0016 | 0.0009 | 0.01 | 1.6 | 372.4 | 0.0009 | 0.01 | 1.6 | 374.4 |
Olfactory | 6.75 | 0.0002 | 0.0001 | 0.00 | 0.2 | 46.7 | 0.0001 | 0.00 | 0.2 | 46.9 |
Pharynx | 1.32 | 0.0002 | 0.0001 | 0.00 | 0.2 | 44.0 | 0.0001 | 0.00 | 0.2 | 44.3 |
Larynx | 0.38 | 0.0032 | 0.0017 | 0.02 | 3.1 | 737.2 | 0.0018 | 0.02 | 3.1 | 741.2 |
Total | 17.39 | 0.5855 | 0.3197 | 3.3982 | 564.1 | 135,384.0 | 0.3214 | 3.4163 | 567.1 | 136,104.0 |
Table 5. Cumulative mass deposited and retained in the tracheobronchial and pulmonary regions of the Symmetric and Asymmetric Sprague Dawley rat models (EPA v1.01) at the end of a 4-hr exposure to 2.75 μm MMAD particles at 5 mg/L air concentration.
Region |
SD Rat Model | Cumulative Mass Deposited in 4- hr (mg) |
Retained Mass at 4-hr (mg) |
Fraction Retained at 4- hr |
Retained Mass at 7 days (mg) |
Fraction Retained at 7 days |
TB | Symmetric | 93.2 | 20.3 | 0.22 | 0.0559 | 0.0006 |
Alveolar | Symmetric | 15.6 | 15.6 | 1.00 | 9.94 | 0.9819 |
TB | Asymmetric | 87 | 23.3 | 0.27 | 0.07 | 0.0008 |
Alveolar | Asymmetric | 20 | 20 | 1.00 | 13.60 | 0.87 |
Table 4. Theoretical distributions of the fractions of deposited mass estimated for the head region of the human MPPD simulations based upon published computational fluid particle dynamics (CFPD) simulations with comparable aerosols (Corley et al., 2001).
From Tables 4 and 5, Corley et al. (2021) | Normalized Deposition in MPPD Head Region (v3.041) | |||||
Nose Breathing | Nose Breathing (Resting) | |||||
Airway Region |
Surf. Area (cm2) |
Dep. Fract. (a) |
Est. Dep. Fract. | Est. Dep Mass Rate (µg/Breath) |
Est. Dep Mass Rate (µg/min) |
Est. Total Dep Mass 4-hr (µg) |
Vestibule | 33.0 | 0.00034 | 0.0269 | 83.9 | 1,006.9 | 241,656.6 |
Respiratory | 181.4 | 0.00359 | 0.2849 | 890.3 | 10,683.0 | 2,563,930.8 |
Olfactory | 21.3 | 0.00033 | 0.0258 | 80.6 | 966.7 | 232,013.1 |
Pharynx | 29.1 | 0.00048 | 0.0381 | 119.1 | 1,429.5 | 343,068.4 |
Larynx | 33.0 | 0.00164 | 0.1297 | 405.3 | 4,863.9 | 1,167,331.1 |
Total | 297.732 | 0.00637 | 0.5054 | 1,579.2 | 18,950.0 | 4,548,000.0 |
Oral Breathing | Oral Breathing | |||||
Mouth | 77.8 | 0.00597 | 0.0226 | 70.58 | 846.9 | 203,263.1 |
Oropharynx | 44.0 | 0.00070 | 0.0026 | 8.23 | 98.7 | 23,693.1 |
Larynx | 33.9 | 0.00155 | 0.0059 | 18.36 | 220.3 | 52,883.8 |
Total | 155.6 | 0.00822 | 0.0311 | 97.17 | 1,166.0 | 279,840.0 |
a) Interpolated from deposition fractions in airway regions for 2.75 μm aerosols from 1 and 3 μm aerosol simulations (Tables 4 and 5, Corley et al. (2021)).
Table 5. Cumulative mass deposited and retained in the tracheobronchial and pulmonary regions of the Symmetric Yeh and Schum human models (v3.041) for each breathing mode at the end of a 4-hr exposure to 2.75 μm MMAD particles at 5 mg/L air concentration.
Region |
Breathing Mode | Cumulative Mass Deposited in 4- hr (mg) |
Retained Mass at 4-hr (mg) |
Fraction Retained at 4- hr |
Retained Mass at 7 days (mg) |
Fraction Retained at 7 days |
TB | Nasal, Resting | 754 | 613 | 0.81 | 11.3 | 0.015 |
TB | Nasal, Lt. Exercise |
887 |
591 |
0.67 |
20.7 |
0.023 |
TB | Oral, Resting | 1,186 | 963 | 0.81 | 17.8 | 0.015 |
TB | Oral, Lt. Exercise | 2,569 | 1,710 | 0.67 | 60.0 | 0.023 |
TB | Oronasal, Heavy Exercise |
3,928 |
2,090 |
0.53 |
71.3 |
0.018 |
Alveolar | Nasal, Resting | 1,765 | 1,760 | 1.00 | 1,690 | 0.957 |
Alveolar | Nasal, Lt. Exercise |
3,144 |
3,140 |
1.00 |
3,010 |
0.957 |
Alveolar | Oral, Resting | 2,771 | 2,770 | 1.00 | 2,660 | 0.960 |
Alveolar | Oral, Lt. Exercise | 9,115 | 9,110 | 1.00 | 8,720 | 0.957 |
Alveolar | Oronasal, Heavy Exercise |
10,540 |
10,500 |
1.00 |
10,100 |
0.958 |
Table 6. Aerosol deposition by generation (all airways in each generation) in the Symmetric Yeh and Schum human model (v3.041) following a 4-hr exposure to 2.75 µm MMAD particles at 5 mg/L air concentration for nasal breathing under resting conditions.
Generation |
Airway |
Surface Area (cm2) |
Dep Fraction |
Dep Mass Rate (µg/Breath) |
Dep Mass Rate (µg/min) |
Dep Mass Rate (µg/min/cm2) |
Total Dep Mass 4-hr (µg) |
Total Dep Particles (no.) | Total Dep Mass 4- hr (µg/cm2) |
1 | TB | 4.46E+01 | 0.0000 | 0.08 | 1.01 | 0.02 | 242.5 | 2.23E+07 | 5.44 |
2 | TB | 3.02E+01 | 0.0026 | 8.25 | 99.00 | 3.28 | 23,760.0 | 2.18E+09 | 787.02 |
3 | TB | 1.79E+01 | 0.0023 | 7.17 | 86.04 | 4.82 | 20,649.6 | 1.90E+09 | 1,156.19 |
4 | TB | 1.42E+01 | 0.0015 | 4.71 | 56.52 | 3.99 | 13,564.8 | 1.25E+09 | 957.29 |
5 | TB | 2.30E+01 | 0.0014 | 4.50 | 54.00 | 2.35 | 12,960.0 | 1.19E+09 | 563.48 |
6 | TB | 4.12E+01 | 0.0015 | 4.77 | 57.24 | 1.39 | 13,737.6 | 1.26E+09 | 333.68 |
7 | TB | 5.50E+01 | 0.0016 | 5.09 | 61.08 | 1.11 | 14,659.2 | 1.35E+09 | 266.58 |
8 | TB | 1.02E+02 | 0.0023 | 7.08 | 84.96 | 0.83 | 20,390.4 | 1.87E+09 | 200.10 |
9 | TB | 1.59E+02 | 0.0032 | 10.00 | 120.00 | 0.76 | 28,800.0 | 2.64E+09 | 181.59 |
10 | TB | 1.95E+02 | 0.0038 | 11.80 | 141.60 | 0.73 | 33,984.0 | 3.12E+09 | 174.46 |
11 | TB | 2.50E+02 | 0.0045 | 14.10 | 169.20 | 0.68 | 40,608.0 | 3.73E+09 | 162.30 |
12 | TB | 3.16E+02 | 0.0055 | 17.10 | 205.20 | 0.65 | 49,248.0 | 4.52E+09 | 155.75 |
13 | TB | 3.85E+02 | 0.0063 | 19.70 | 236.40 | 0.61 | 56,736.0 | 5.21E+09 | 147.33 |
14 | TB | 4.60E+02 | 0.0085 | 26.60 | 319.20 | 0.69 | 76,608.0 | 7.04E+09 | 166.54 |
15 | TB | 5.63E+02 | 0.0099 | 31.00 | 372.00 | 0.66 | 89,280.0 | 8.20E+09 | 158.66 |
16 | TB | 7.33E+02 | 0.0123 | 38.40 | 460.80 | 0.63 | 110,592.0 | 1.02E+10 | 150.88 |
17 | TB | 1.05E+03 | 0.0165 | 51.60 | 619.20 | 0.59 | 148,608.0 | 1.36E+10 | 141.26 |
18 | Pulmonary | 4.56E+03 | 0.0249 | 77.90 | 934.80 | 0.21 | 224,352.0 | 2.06E+10 | 49.25 |
19 | Pulmonary | 1.13E+04 | 0.0318 | 99.50 | 1194.00 | 0.11 | 286,560.0 | 2.63E+10 | 25.45 |
20 | Pulmonary | 3.54E+04 | 0.0436 | 136.00 | 1632.00 | 0.05 | 391,680.0 | 3.60E+10 | 11.06 |
21 | Pulmonary | 5.71E+04 | 0.0522 | 163.00 | 1956.00 | 0.03 | 469,440.0 | 4.31E+10 | 8.22 |
22 | Pulmonary | 1.00E+05 | 0.0416 | 130.00 | 1560.00 | 0.02 | 374,400.0 | 3.44E+10 | 3.73 |
23 | Pulmonary | 1.79E+05 | 0.0021 | 6.47 | 77.64 | 0.00 | 18,633.6 | 1.71E+09 | 0.10 |
24 | Pulmonary | 3.30E+05 | 0.0000 | 0.00 | 0.00 | 0.00 | 0.0 | 0.00E+00 | 0.00 |
Table 7. Aerosol deposition by generation (all airways in each generation) in the Symmetric Yeh and Schum human model (v3.041) following a 4-hr exposure to 2.75 µm MMAD particles at 5 mg/L air concentration for nasal breathing under light exercise conditions.
Generation |
Airway |
Surface Area (cm2) |
Dep Fraction |
Dep Mass Rate (µg/Breath) |
Dep Mass Rate (µg/min) |
Dep Mass Rate (µg/min/cm2) |
Total Dep Mass 4- hr (µg) |
Total Dep Particles (no.) | Total Dep Mass 4- hr (µg/cm2) |
1 | TB | 4.46E+01 | 2.13E-06 | 0.01 | 0.27 | 0.01 | 63.8 | 5.86E+06 | 1.43 |
2 | TB | 3.02E+01 | 2.41E-03 | 15.10 | 302.00 | 10.00 | 72,480.0 | 6.66E+09 | 2,400.79 |
3 | TB | 1.79E+01 | 2.13E-03 | 13.30 | 266.00 | 14.89 | 63,840.0 | 5.86E+09 | 3,574.47 |
4 | TB | 1.42E+01 | 1.40E-03 | 8.75 | 175.00 | 12.35 | 42,000.0 | 3.86E+09 | 2,964.01 |
5 | TB | 2.30E+01 | 1.29E-03 | 8.09 | 161.80 | 7.03 | 38,832.0 | 3.57E+09 | 1,688.35 |
6 | TB | 4.12E+01 | 1.09E-03 | 6.82 | 136.40 | 3.31 | 32,736.0 | 3.01E+09 | 795.14 |
7 | TB | 5.50E+01 | 8.99E-04 | 5.62 | 112.40 | 2.04 | 26,976.0 | 2.48E+09 | 490.56 |
8 | TB | 1.02E+02 | 1.07E-03 | 6.66 | 133.20 | 1.31 | 31,968.0 | 2.94E+09 | 313.72 |
9 | TB | 1.59E+02 | 1.22E-03 | 7.60 | 152.00 | 0.96 | 36,480.0 | 3.35E+09 | 230.01 |
10 | TB | 1.95E+02 | 1.12E-03 | 6.98 | 139.60 | 0.72 | 33,504.0 | 3.08E+09 | 171.99 |
11 | TB | 2.50E+02 | 1.36E-03 | 8.52 | 170.40 | 0.68 | 40,896.0 | 3.76E+09 | 163.45 |
12 | TB | 3.16E+02 | 1.55E-03 | 9.71 | 194.20 | 0.61 | 46,608.0 | 4.28E+09 | 147.40 |
13 | TB | 3.85E+02 | 1.74E-03 | 10.90 | 218.00 | 0.57 | 52,320.0 | 4.80E+09 | 135.86 |
14 | TB | 4.60E+02 | 2.24E-03 | 14.00 | 280.00 | 0.61 | 67,200.0 | 6.17E+09 | 146.09 |
15 | TB | 5.63E+02 | 2.57E-03 | 16.10 | 322.00 | 0.57 | 77,280.0 | 7.10E+09 | 137.34 |
16 | TB | 7.33E+02 | 3.21E-03 | 20.10 | 402.00 | 0.55 | 96,480.0 | 8.86E+09 | 131.62 |
17 | TB | 1.05E+03 | 4.26E-03 | 26.60 | 532.00 | 0.51 | 127,680.0 | 1.17E+10 | 121.37 |
18 | Pulmonary | 4.56E+03 | 6.55E-03 | 40.90 | 818.00 | 0.18 | 196,320.0 | 1.80E+10 | 43.10 |
19 | Pulmonary | 1.13E+04 | 8.88E-03 | 55.50 | 1110.00 | 0.10 | 266,400.0 | 2.45E+10 | 23.66 |
20 | Pulmonary | 3.54E+04 | 1.35E-02 | 84.60 | 1692.00 | 0.05 | 406,080.0 | 3.73E+10 | 11.47 |
21 | Pulmonary | 5.71E+04 | 2.01E-02 | 126.00 | 2520.00 | 0.04 | 604,800.0 | 5.55E+10 | 10.59 |
22 | Pulmonary | 1.00E+05 | 2.77E-02 | 173.00 | 3460.00 | 0.03 | 830,400.0 | 7.63E+10 | 8.28 |
23 | Pulmonary | 1.79E+05 | 2.61E-02 | 163.00 | 3260.00 | 0.02 | 782,400.0 | 7.19E+10 | 4.37 |
24 | Pulmonary | 3.30E+05 | 1.93E-03 | 12.00 | 240.00 | 0.00 | 57,600.0 | 5.29E+09 | 0.17 |
Table 8. Aerosol deposition by generation (all airways in each generation) in the Symmetric Yeh and Schum human model (v3.041) following a 4-hr exposure to 2.75 µm MMAD particles at 5 mg/L air concentration for oral breathing under resting conditions.
Generation |
Airway |
Surface Area (cm2) |
Dep Fraction |
Dep Mass Rate (µg/Breath) |
Dep Mass Rate (µg/min) |
Dep Mass Rate (µg/min/cm2) |
Total Dep Mass 4- hr (µg) |
Total Dep Particles (no.) | Total Dep Mass 4- hr (µg/cm2) |
1 | TB | 4.46E+01 | 4.24E-05 | 0.13 | 1.5888 | 0.04 | 381.312 | 3.50E+07 | 8.5 |
2 | TB | 3.02E+01 | 4.15E-03 | 13.00 | 156 | 5.17 | 37440 | 3.44E+09 | 1240.1 |
3 | TB | 1.79E+01 | 3.61E-03 | 11.30 | 135.6 | 7.59 | 32544 | 2.99E+09 | 1822.2 |
4 | TB | 1.42E+01 | 2.37E-03 | 7.41 | 88.92 | 6.28 | 21340.8 | 1.96E+09 | 1506.1 |
5 | TB | 2.30E+01 | 2.26E-03 | 7.07 | 84.84 | 3.69 | 20361.6 | 1.87E+09 | 885.3 |
6 | TB | 4.12E+01 | 2.40E-03 | 7.49 | 89.88 | 2.18 | 21571.2 | 1.98E+09 | 524.0 |
7 | TB | 5.50E+01 | 2.56E-03 | 7.99 | 95.88 | 1.74 | 23011.2 | 2.11E+09 | 418.5 |
8 | TB | 1.02E+02 | 3.56E-03 | 11.10 | 133.2 | 1.31 | 31968 | 2.94E+09 | 313.7 |
9 | TB | 1.59E+02 | 5.04E-03 | 15.70 | 188.4 | 1.19 | 45216 | 4.15E+09 | 285.1 |
10 | TB | 1.95E+02 | 5.93E-03 | 18.50 | 222 | 1.14 | 53280 | 4.89E+09 | 273.5 |
11 | TB | 2.50E+02 | 7.10E-03 | 22.20 | 266.4 | 1.06 | 63936 | 5.87E+09 | 255.5 |
12 | TB | 3.16E+02 | 8.62E-03 | 26.90 | 322.8 | 1.02 | 77472 | 7.11E+09 | 245.0 |
13 | TB | 3.85E+02 | 9.93E-03 | 31.00 | 372 | 0.97 | 89280 | 8.20E+09 | 231.8 |
14 | TB | 4.60E+02 | 1.34E-02 | 41.80 | 501.6 | 1.09 | 120384 | 1.11E+10 | 261.7 |
15 | TB | 5.63E+02 | 1.56E-02 | 48.70 | 584.4 | 1.04 | 140256 | 1.29E+10 | 249.3 |
16 | TB | 7.33E+02 | 1.93E-02 | 60.40 | 724.8 | 0.99 | 173952 | 1.60E+10 | 237.3 |
17 | TB | 1.05E+03 | 2.60E-02 | 81.10 | 973.2 | 0.93 | 233568 | 2.14E+10 | 222.0 |
18 | Pulmonary | 4.56E+03 | 3.92E-02 | 122.00 | 1464 | 0.32 | 351360 | 3.23E+10 | 77.1 |
19 | Pulmonary | 1.13E+04 | 5.00E-02 | 156.00 | 1872 | 0.17 | 449280 | 4.13E+10 | 39.9 |
20 | Pulmonary | 3.54E+04 | 6.84E-02 | 214.00 | 2568 | 0.07 | 616320 | 5.66E+10 | 17.4 |
21 | Pulmonary | 5.71E+04 | 8.20E-02 | 256.00 | 3072 | 0.05 | 737280 | 6.77E+10 | 12.9 |
22 | Pulmonary | 1.00E+05 | 6.54E-02 | 204.00 | 2448 | 0.02 | 587520 | 5.40E+10 | 5.9 |
23 | Pulmonary | 1.79E+05 | 3.26E-03 | 10.20 | 122.4 | 0.00 | 29376 | 2.70E+09 | 0.2 |
24 | Pulmonary | 3.30E+05 | 0.00E+00 | 0.00 | 0 | 0.00 | 0 | 0.00E+00 | 0.0 |
Table 9. Aerosol deposition by generation (all airways in each generation) in the Symmetric Yeh and Schum human model (v3.041) following a 4-hr exposure to 2.75 µm MMAD particles at 5 mg/L air concentration for oral breathing under light exercise conditions.
Generation |
Airway |
Surface Area (cm2) |
Dep Fraction |
Dep Mass Rate (µg/Breath) |
Dep Mass Rate (µg/min) |
Dep Mass Rate (µg/min/cm2) |
Total Dep Mass 4-hr (µg) |
Total Dep Particles (no.) | Total Dep Mass 4- hr (µg/cm2) |
1 | TB | 4.46E+01 | 6.18E-06 | 0.04 | 0.77 | 0.02 | 185.3 | 1.70E+07 | 4.2 |
2 | TB | 3.02E+01 | 6.98E-03 | 43.6 | 872.0 | 28.88 | 209280.0 | 1.92E+10 | 6932.1 |
3 | TB | 1.79E+01 | 6.18E-03 | 38.6 | 772.0 | 43.23 | 185280.0 | 1.70E+10 | 10374.0 |
4 | TB | 1.42E+01 | 4.06E-03 | 25.4 | 508.0 | 35.85 | 121920.0 | 1.12E+10 | 8604.1 |
5 | TB | 2.30E+01 | 3.75E-03 | 23.4 | 468.0 | 20.35 | 112320.0 | 1.03E+10 | 4883.5 |
6 | TB | 4.12E+01 | 3.16E-03 | 19.8 | 396.0 | 9.62 | 95040.0 | 8.73E+09 | 2308.5 |
7 | TB | 5.50E+01 | 2.61E-03 | 16.3 | 326.0 | 5.93 | 78240.0 | 7.19E+09 | 1422.8 |
8 | TB | 1.02E+02 | 3.09E-03 | 19.3 | 386.0 | 3.79 | 92640.0 | 8.51E+09 | 909.1 |
9 | TB | 1.59E+02 | 3.52E-03 | 22.0 | 440.0 | 2.77 | 105600.0 | 9.70E+09 | 665.8 |
10 | TB | 1.95E+02 | 3.24E-03 | 20.2 | 404.0 | 2.07 | 96960.0 | 8.90E+09 | 497.7 |
11 | TB | 2.50E+02 | 3.95E-03 | 24.7 | 494.0 | 1.97 | 118560.0 | 1.09E+10 | 473.9 |
12 | TB | 3.16E+02 | 4.50E-03 | 28.1 | 562.0 | 1.78 | 134880.0 | 1.24E+10 | 426.6 |
13 | TB | 3.85E+02 | 5.03E-03 | 31.4 | 628.0 | 1.63 | 150720.0 | 1.38E+10 | 391.4 |
14 | TB | 4.60E+02 | 6.48E-03 | 40.5 | 810.0 | 1.76 | 194400.0 | 1.79E+10 | 422.6 |
15 | TB | 5.63E+02 | 7.45E-03 | 46.5 | 930.0 | 1.65 | 223200.0 | 2.05E+10 | 396.7 |
16 | TB | 7.33E+02 | 9.30E-03 | 58.2 | 1,164.0 | 1.59 | 279360.0 | 2.57E+10 | 381.1 |
17 | TB | 1.05E+03 | 1.23E-02 | 77.1 | 1,542.0 | 1.47 | 370080.0 | 3.40E+10 | 351.8 |
18 | Pulmonary | 4.56E+03 | 1.90E-02 | 119.0 | 2,380.0 | 0.52 | 571200.0 | 5.25E+10 | 125.4 |
19 | Pulmonary | 1.13E+04 | 2.57E-02 | 161.0 | 3,220.0 | 0.29 | 772800.0 | 7.10E+10 | 68.6 |
20 | Pulmonary | 3.54E+04 | 3.92E-02 | 245.0 | 4,900.0 | 0.14 | 1176000.0 | 1.08E+11 | 33.2 |
21 | Pulmonary | 5.71E+04 | 5.82E-02 | 364.0 | 7,280.0 | 0.13 | 1747200.0 | 1.60E+11 | 30.6 |
22 | Pulmonary | 1.00E+05 | 8.03E-02 | 502.0 | 10,040.0 | 0.10 | 2409600.0 | 2.21E+11 | 24.0 |
23 | Pulmonary | 1.79E+05 | 7.57E-02 | 473.0 | 9,460.0 | 0.05 | 2270400.0 | 2.08E+11 | 12.7 |
24 | Pulmonary | 3.30E+05 | 5.59E-03 | 34.9 | 698.0 | 0.00 | 167520.0 | 1.54E+10 | 0.5 |
Table 10. Aerosol deposition by generation (all airways in each generation) in the Symmetric Yeh and Schum human model (v3.041) following a 4-hr exposure to 2.75 µm MMAD particles at 5 mg/L air concentration for oronasal (normal augmenter) breathing under heavy exercise conditions.
Generation |
Airway |
Surface Area (cm2) |
Dep Fraction |
Dep Mass Rate (µg/Breath) |
Dep Mass Rate (µg/min) |
Dep Mass Rate (µg/min/cm2) |
Total Dep Mass 4-hr (µg) |
Total Dep Particles (no.) | Total Dep Mass 4- hr (µg/cm2) |
1 | TB | 4.46E+01 | 2.84E-06 | 0.03 | 0.71 | 0.02 | 170.4 | 1.56E+07 | 3.8 |
2 | TB | 3.02E+01 | 7.81E-03 | 75.1 | 1952.60 | 64.68 | 468,624.0 | 4.30E+10 | 15,522.5 |
3 | TB | 1.79E+01 | 7.01E-03 | 67.4 | 1752.40 | 98.12 | 420,576.0 | 3.86E+10 | 23,548.5 |
4 | TB | 1.42E+01 | 4.92E-03 | 47.3 | 1229.80 | 86.79 | 295,152.0 | 2.71E+10 | 20,829.4 |
5 | TB | 2.30E+01 | 4.85E-03 | 46.6 | 1211.60 | 52.68 | 290,784.0 | 2.67E+10 | 12,642.8 |
6 | TB | 4.12E+01 | 3.91E-03 | 37.6 | 977.60 | 23.75 | 234,624.0 | 2.15E+10 | 5,698.9 |
7 | TB | 5.50E+01 | 2.70E-03 | 25.9 | 673.40 | 12.25 | 161,616.0 | 1.48E+10 | 2,939.0 |
8 | TB | 1.02E+02 | 3.10E-03 | 29.8 | 774.80 | 7.60 | 185,952.0 | 1.71E+10 | 1,824.8 |
9 | TB | 1.59E+02 | 2.97E-03 | 28.5 | 741.00 | 4.67 | 177,840.0 | 1.63E+10 | 1,121.3 |
10 | TB | 1.95E+02 | 2.15E-03 | 20.6 | 535.60 | 2.75 | 128,544.0 | 1.18E+10 | 659.9 |
11 | TB | 2.50E+02 | 2.62E-03 | 25.2 | 655.20 | 2.62 | 157,248.0 | 1.44E+10 | 628.5 |
12 | TB | 3.16E+02 | 2.78E-03 | 26.7 | 694.20 | 2.20 | 166,608.0 | 1.53E+10 | 526.9 |
13 | TB | 3.85E+02 | 2.93E-03 | 28.2 | 733.20 | 1.90 | 175,968.0 | 1.62E+10 | 456.9 |
14 | TB | 4.60E+02 | 3.53E-03 | 33.9 | 881.40 | 1.92 | 211,536.0 | 1.94E+10 | 459.9 |
15 | TB | 5.63E+02 | 3.84E-03 | 36.9 | 959.40 | 1.70 | 230,256.0 | 2.11E+10 | 409.2 |
16 | TB | 7.33E+02 | 4.66E-03 | 44.8 | 1164.80 | 1.59 | 279,552.0 | 2.57E+10 | 381.4 |
17 | TB | 1.05E+03 | 5.71E-03 | 54.9 | 1427.40 | 1.36 | 342,576.0 | 3.15E+10 | 325.6 |
18 | Pulmonary | 4.56E+03 | 8.33E-03 | 80.1 | 2082.60 | 0.46 | 499,824.0 | 4.59E+10 | 109.7 |
19 | Pulmonary | 1.13E+04 | 1.12E-02 | 108.0 | 2808.00 | 0.25 | 673,920.0 | 6.19E+10 | 59.9 |
20 | Pulmonary | 3.54E+04 | 1.73E-02 | 167.0 | 4342.00 | 0.12 | 1,042,080.0 | 9.57E+10 | 29.4 |
21 | Pulmonary | 5.71E+04 | 2.69E-02 | 258.0 | 6708.00 | 0.12 | 1,609,920.0 | 1.48E+11 | 28.2 |
22 | Pulmonary | 1.00E+05 | 4.09E-02 | 393.0 | 10218.00 | 0.10 | 2,452,320.0 | 2.25E+11 | 24.4 |
23 | Pulmonary | 1.79E+05 | 5.05E-02 | 486.0 | 12636.00 | 0.07 | 3,032,640.0 | 2.78E+11 | 17.0 |
24 | Pulmonary | 3.30E+05 | 2.05E-02 | 197.0 | 5122.00 | 0.02 | 1,229,280.0 | 1.13E+11 | 3.7 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- > 1 - < 5 mg/L air
- Physical form:
- inhalation: aerosol
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Acute inhalation toxicity study (rat)
In a procedure following OECD guideline 403 and GLP, five male and five female albino rats per group were exposed to the test substance by nose-only inhalation for four hours at gravimetrically determined mean concentrations of 1.1 and 5.2 mg/L air. All animals were observed for clinical signs and mortality during the inhalation exposure and the subsequent 14-day observation period or until they were found dead. Body weights were recorded prior to exposure on test day 0 (acclimatization period), and during the observation period on test days 1, 3 and 7 before necropsy and weekly thereafter, or before the sacrifice of the animals at the end of the observation period. At the end of the observation period, all animals were sacrificed and necropsied. Animals which died were necropsied as soon as they were found dead. All animals exposed to 5.2 mg/l air died within two days after exposure start. All animals exposed to 1.1 mg/L air survived the scheduled observation period.
Clinical signs of toxicity in animals exposed to 1.1 mg/L comprised accelerated respiration, intermittent respiration, abdominal respiration, respiration sounds, feces substance like discolored, piloerection, substance-discolored fur and substance-contaminated fur. Findings were observed in the males from hour 1 of exposure through study day 11. No findings were detected in the male animals during the post-exposure observation period from study day 12 onwards. Findings were observed in the females from hour 1 of exposure until the end of the post-exposure observation period. No gross pathological findings were noted during the necropsy of the animals at the termination of the post-exposure observation period.
Clinical signs of toxicity in animals exposed to 5.2 mg/L comprised accelerated respiration, depressed respiration, abdominal respiration, no feces, activity: attention reduced, piloerection, substance-discolored fur and substance-contaminated fur. Findings were observed from hour 1 of exposure until the death of the animals. The mean body weights of the surviving animals decreased during the first post-exposure observation days. During necropsy of the dead five male and five female animals, many black foci were seen in the lung lobes with sunken surface. Blue discoloration of content of the stomach was seen in four males and three females and blue depositions in the trachea were present in four males and two females. For further evaluation, histopathological examinations of the respiratory tract (nasal cavity, larynx, pharynx, trachea, and lung) from three animals were performed. The lung showed large amount of blue pigment within the bronchi, bronchioles and terminal bronchioles, leading to obstruction of the airways in two animals with one of them also showing emphysema. The trachea of all examined animals was dilated and contained blue pigment. The larynx at level I - II showed obstruction by blue pigment and large amounts of blue pigment at level III in 2 animals. The third animal presented with large amounts of blue pigment at larynx level I-II and small amounts at the third level. The nasal cavity at level I - IV contained small to moderate amounts of blue pigment. The histopathological findings in the lung, the trachea, and the larynx of animal Nos. 793, 798 and 800 indicate an airway obstruction caused by the inhaled blue pigment as cause of death.
MPPD modulation (rat vs. human)
The Multiple Path Particle Dosimetry (MPPD) model was used to predict aerosol deposition patterns representative of a guideline limit test acute inhalation toxicity study in the Sprague Dawley rat. Specifically, a 4-hr nose-only inhalation exposure to generic aerosol particles having a mass median aerosol diameter (MMAD) of 2.75 µm and a geometric standard deviation (GSD) of 1.0 (i.e., monodisperse distribution), a unit density of 1 g/cm3, and an airborne concentration of 5000 mg/m3 (5 mg/L) was simulated. Human simulations for a variety of hypothetical activity and breathing conditions for the same exposure were also conducted to highlight cross-species differences, although it is unlikely that such high aerosol exposures would be considered tolerable, even for non-toxic materials.
Rats are obligate nose breathers and with over 30% of inhalable aerosol depositing in the head region, anterior nasal tissues and laryngeal regions are likely to receive a significant amount of deposition based upon a computational fluid-particle dynamics (CFPD)-informed analysis of MPPD simulations. In general, greater deposition of aerosols occurs in the head region of humans following nasal than with oral breathing. However, oral breathing and increased activity (increased bpm and minute volume) can lead to deeper penetration of aerosols within the pulmonary region. Given the smaller airways and higher breathing frequencies and minute volumes per unit body weight in rats vs. humans, greater amounts of aerosol mass are deposited in the tracheobronchial region in rats, while in humans, a greater mass is deposited in the pulmonary region. However, when normalized to airway surface areas, both species receive a relatively low overall pulmonary regional dose. Mucociliary clearance rates are also slower in humans than in the rat and the time to clear tracheobronchial airways varies between ~48 and 72 hr depending upon breathing mode and activity level vs. ~12 hr in the rat. Both species have slow macrophage clearance rates in the pulmonary region with neither species clearing much material (<87-97% of deposited mass) by 7 days.
However, given the smaller airways in the rat and the potential for significant amounts of deposited and retained mass of aerosols in individual airways, the potential for airway obstruction and resulting decreases in airflows and pulmonary function was assessed in individual airways using a geometric analysis of MPPD simulations. This analysis showed that a significant percentage of pulmonary airways and to a lesser extent, bronchiolar airways, may be at risk of occlusion and impairment of lung function and gas exchange in the rat. Such a potential for physical impact on lung function for certain materials that are presumed to be of low toxicity raises questions for assessing acute toxicity risks for humans based upon guideline acute toxicity studies in the rat at limit test concentrations.
WOE justification for classification
Current OECD guidelines for acute inhalation toxicity assessments
incorporate a limit test aerosol concentration for poorly soluble
particles that are either known or expected to be virtually non-toxic
(OECD, 2009). Depending upon regulatory requirements, the limit test
concentration for aerosols can be as high as 5 mg/L (or the maximum
attainable concentration) if the United Nations (UN) Globally Harmonized
System of Classification and Labelling of Chemicals (GHS) is used.
During the acute dust exposure study (GLP, OECD 403), rats exposed to 5
mg/L of the test substance died of suffocation after agglutinated
pigment blocked the airways, whereas all rats survived the 4h dust
exposure at the low dose of 1 mg/L.
It is widely recognized that external exposure concentrations of
airborne particulates are not directly equivalent to the amounts that
are inhaled, deposited, and retained in airways of laboratory animals
and humans due to major differences in airway anatomy and physiology. In
line with this, with regard to dose adjustment, the ECHA R.8 document on
“Characterisation of dose[concentration]-response for human health”
(Version 2.1, 2012) suggests to account for differences in respiratory
rates of the experimental animal (at rest) and the human as well as for
the increased respiratory rate of a worker, when inhalation DNELs are
derived.
Without factoring in these species differences, results from inhalation
toxicity studies are not directly translatable to human health risk.
Accordingly, the results from the acute inhalation study on rats alone
are regarded as insufficient to derive a potential human health hazard
posed by the test substance.
Therefore, additional computational approaches that incorporate
species-specific anatomy, physiology, and the physics of aerosol
transport and deposition were utilized to assess whether the results
from the acute inhalation study is relevant for humans.
Focusing upon acute toxicity testing guidelines, the MPPD model was
applied to provide a generic (not chemical-specific) respiratory
dosimetry assessment of rats exposed in nose-only inhalation chambers
for 4-hr to aerosols with a respirable particle size of 2.75 µm mass
median aerosol diameter (MMAD) and a geometric standard deviation (GSD)
of 1.0 at a limit test concentration of 5 mg/L – similar to the settings
of the in vivo study and analog to the particle properties of the test
item used. Particular emphasis was placed upon particle load and
retention in individual airways to assess potential vulnerabilities for
physical obstruction of bronchial and pulmonary airways in the rat due
to high rates of local aerosol deposition. In addition, human
simulations for a variety of hypothetical activity and breathing
conditions for the same exposure were also conducted to highlight
cross-species differences, although it is unlikely that such high
aerosol exposures would be considered tolerable, even for non-toxic
materials.
As a result, the MPPD simulations indicate that the results from the
high dose group of the acute dust exposure study (GLP, OECD 403) in rats
are not relevant for resting or light exercising humans, since deviating
internal exposure patterns of rat and humans were observed.
The major difference between both species is that 50% of the material is
deposited in the head-region in humans (only 30% in rats) and can be
blown or spit out. Moreover, at tracheobronchial and bronchial level,
the rat receives ~5-10-fold higher dose/cm2 airway surface (when
cumulative deposited mass is normalized to respective airway surface
areas) than the human under resting nasal breathing ventilation
conditions. The pulmonary region of humans receives a greater fraction
of inhaled aerosol than the rat, though when normalized to airway
surface areas, both species receive a relatively low overall pulmonary
regional dose.
As to the applicability of limit test concentrations for aerosols with
presumed low toxicity in guideline acute inhalation toxicity studies
with rats, the potential for airway obstruction which could lead to
decreases in airflows and pulmonary function was assessed using a
geometric analysis of MPPD simulations. Given the smaller airways in the
rat and the potential for significant amounts of deposited and retained
mass of aerosols during a 4-hr nose-only exposure to aerosols at 5 mg/L
atmospheric concentrations, the size (diameter) of retained masses in
each airway segment were compared with their corresponding airway
diameter. In this analysis, which assumed that the total retained mass
in each airway at the end of the 4-hr exposure formed one spherical
particle, a significant a percentage of pulmonary airways and to a
lesser extent bronchiolar airways may be at risk of occlusion and
impairment of gas-exchange. Such a potential for physical impact on
pulmonary function under limit test exposure conditions for certain
materials that are presumed to be of low toxicity raises questions for
assessing acute toxicity risks for humans.
Finally, in comparison to the rat, more material is deposited in the
head regions in human. Second, the wider airways in human hamper fast
agglutination of the test material and therefore obstruction of the
airways. At last, a 4h-exposure of worker to such high concentrations is
rather unlikely even in case of an accident. The suffocation at 5 mg/L
as observed in rats is therefore not regarded as relevant for humans and
a classification as acute cat. 4 H332 not justified.
Justification for classification or non-classification
Classification, Labelling, and Packaging Regulation (EC) No. 1272/2008
The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. No mortality occurred at the limit dose of 2000 mg/kg bw. As a result the substance is not considered to be classified for acute oral and dermal toxicity under Regulation (EC) No. 1272/2008. The LC50 for acute dust inhalation exposure is > 1mg/L and less than 5 mg/L. However, MPPD model in rat and human simulations indicate that the results from the high dose group of the acute dust exposure study (GLP, OECD 403) in rats is not relevant for humans, since deviating internal exposure patterns of rat and humans were observed. According to CLP Annex I, weight of evidence and expert judgement, no classification for acute inhalation toxicity is warranted, as there is no relevance for human health.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
